copper peptide ghk-cu hair growth study clinical for Growth: Protocols ghk-cu hair growth clinical study

The FDA classifies substances intended for administration to humans without approved status as adulterated or misbranded drugs under federal law, meaning commercial products sold as injectable BPC-157 for human use violate federal regulations

In addition, it does not require post-cycle therapy

Liposomal delivery systems encapsulate AHK-Cu in lipid spheres, potentially improving penetration through the stratum corneum and protecting the peptide from degradation

If the solution has precipitated (which can happen if it was frozen or refrigerated improperly), do not inject unless warming the vial to body temperature has fully dissolved the precipitates